Vinorelbine

Vinorelbine
Clinical data
Trade names Navelbine
AHFS/Drugs.com Monograph
MedlinePlus a695013
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
Routes of
administration		 intravenous, by mouth[1]
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 43 ± 14% (oral)[2]
Protein binding 79 to 91%
Metabolism liver (CYP3A4-mediated)
Biological half-life 27.7 to 43.6 hours
Excretion Fecal (46%) and kidney (18%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C45H54N4O8
Molar mass 778.932 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Vinorelbine (NVB), sold under the brand name Navelbine among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer and non-small cell lung cancer.[3] It is given by injection into a vein or by mouth.[3][1]

Common side effects include bone marrow suppression, pain at the site of injection, vomiting, feeling tired, numbness, and diarrhea. Other serious side effects include shortness of breath. Use during pregnancy may harm the baby.[3] Vinorelbine is in the vinca alkaloid family of medications.[1] It is believed to work by disrupting the normal function of microtubules and thereby stopping cell division.[3]

Vinorelbine was approved for medical use in the United States in 1994.[3] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] The wholesale price in the developing world as of 2014 is between 18.10 and 42.82 USD per 50 mg vial.[5] This amount in the United Kingdom costs the NHS about 139.00 pounds.[1]

Medical uses

Vinorelbine is approved for the treatment of non-small-cell lung cancer.[6][7] It is used off-label for other cancers such as metastatic breast cancer. It is also active in rhabdomyosarcoma.[8]

Side effects

Vinorelbine has a number of side-effects that can limit its use:

Chemotherapy-induced peripheral neuropathy (a progressive, enduring and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs[9]), lowered resistance to infection, bruising or bleeding, anaemia, constipation, vomitings, diarrhea, nausea, tiredness and a general feeling of weakness (asthenia), inflammation of the vein into which it was injected (phlebitis). Seldom severe hyponatremia is seen.

Less common effects are hair loss and allergic reaction.

Pharmacology

The antitumor activity is due to inhibition of mitosis through interaction with tubulin.[10]

History

Vinorelbine was invented by the pharmacist Pierre Potier and his team from the CNRS in France in the 1980s and was licensed to the oncology department of the Pierre Fabre Group. The drug was approved in France in 1989 under the brand name Navelbine for the treatment of non-small cell lung cancer. It gained approval to treat metastatic breast cancer in 1991. Vinorelbine received approval by the United States Food and Drug Administration (FDA) in December 1994 sponsored by Burroughs Wellcome Company. Pierre Fabre Group now markets Navelbine in the U.S., where the drug went generic in February 2003.

In most European countries, vinorelbine is approved to treat non-small cell lung cancer and breast cancer. In the United States it is approved only for non-small cell lung cancer.

Source

The Madagascan periwinkle Catharanthus roseus L. is the source for a number of important natural products, including catharanthine and vindoline[11] and the vinca alkaloids it produces from them: leurosine and the chemotherapy agents vinblastine and vincristine, all of which can be obtained from the plant.[12][13][6][14] The newer semi-synthetic chemotherapeutic agent vinorelbine, which is used in the treatment of non-small-cell lung cancer[6][7] and is not known to occur naturally. However, it can be prepared either from vindoline and catharanthine[6][15] or from leurosine,[16] in both cases by synthesis of anhydrovinblastine. The leurosine pathway uses the Nugent–RajanBabu reagent in a highly chemoselective de-oxygenation of leurosine.[17][16] Anhydrovinblastine is then reacted sequentially with N-bromosuccinimide and trifluoroacetic acid followed by silver tetrafluoroborate to yield vinorelbine.[15]

Oral formulation

An oral formulation has been marketed and registered in most European countries. It has similar efficacy as the intravenous formulation, but it avoids venous toxicities of an infusion and is easier to take. The oral form is not approved in the United States or Australia.

References

  1. 1 2 3 4 British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 594. ISBN 9780857111562.
  2. ↑ Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001). "Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors". Ann Oncol. 12 (11): 1643–9. PMID 11822766. doi:10.1023/A:1013180903805.
  3. 1 2 3 4 5 "Vinorelbine Tartrate". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
  4. ↑ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
  5. ↑ "Vinorelbine". International Drug Price Indicator Guide. Retrieved 28 November 2015.
  6. 1 2 3 4 Keglevich, Péter; Hazai, Laszlo; Kalaus, György; Szántay, Csaba (2012). "Modifications on the basic skeletons of vinblastine and vincristine". Molecules. 17: 5893–5914. PMID 22609781. doi:10.3390/molecules17055893.
  7. 1 2 Faller, Bryan A.; Pandi, Trailokya N. (2011). "Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer". Clinical Medicine Insights: Oncology. 5: 131–144. PMC 3117629 Freely accessible. doi:10.4137/CMO.S5074.
  8. ↑ Casanova, Michela; Ferrari, Andrea; Spreafico, Filippo; Terenziani, Monica; Massimino, Maura; Luksch, Roberto; Cefalo, Graziella; Polastri, Daniela; Marcon, Ilaria; Bellani, Franca Fossati (2002). "Vinorelbine in previously treated advanced childhood sarcomas: Evidence of activity in rhabdomyosarcoma". Cancer. 94 (12): 3263–3268. PMID 12115359. doi:10.1002/cncr.10600.
  9. ↑ del Pino BM. Chemotherapy-induced Peripheral Neuropathy. NCI Cancer Bulletin. Feb 23, 2010;7(4):6.
  10. ↑ Jordan, M. A.; Wilson, L. (2004). "Microtubules as a target for anticancer drugs". Nature Reviews Cancer. 4 (4): 253–265. PMID 15057285. doi:10.1038/nrc1317.
  11. ↑ Hirata, K.; Miyamoto, K.; Miura, Y. (1994). "Catharanthus roseus L. (Periwinkle): Production of Vindoline and Catharanthine in Multiple Shoot Cultures". In Bajaj, Y. P. S. Biotechnology in Agriculture and Forestry 26. Medicinal and Aromatic Plants. VI. Springer-Verlag. pp. 46–55. ISBN 9783540563914.
  12. ↑  Gansäuer, Andreas;  Justicia, José;  Fan, Chun-An;  Worgull, Dennis;  Piestert, Frederik (2007). "Reductive C—C bond formation after epoxide opening via electron transfer". In Krische, Michael J. Metal Catalyzed Reductive C—C Bond Formation: A Departure from Preformed Organometallic Reagents. Topics in Current Chemistry. 279. Springer Science & Business Media. pp. 25–52. ISBN 9783540728795. doi:10.1007/128_2007_130.
  13. ↑ Cooper, Raymond; Deakin, Jeffrey John (2016). "Africa's gift to the world". Botanical Miracles: Chemistry of Plants That Changed the World. CRC Press. pp. 46–51. ISBN 9781498704304.
  14. ↑ Raviña, Enrique (2011). "Vinca alkaloids". The evolution of drug discovery: From traditional medicines to modern drugs. John Wiley & Sons. pp. 157–159. ISBN 9783527326693.
  15. 1 2 Ngo, Quoc Anh; Roussi, Fanny; Cormier, Anthony; Thoret, Sylviane; Knossow, Marcel; Guénard, Daniel; Guéritte, Françoise (2009). "Synthesis and biological evaluation of Vinca alkaloids and phomopsin hybrids". Journal of Medicinal Chemistry. 52 (1): 134–142. PMID 19072542. doi:10.1021/jm801064y.
  16. 1 2 Hardouin, Christophe; Doris, Eric; Rousseau, Bernard; Mioskowski, Charles (2002). "Concise synthesis of anhydrovinblastine from leurosine". Organic Letters. 4 (7): 1151–1153. doi:10.1021/ol025560c.
  17. ↑ Morcillo, Sara P.; Miguel, Delia; Campaña, Araceli G.; Cienfuegos, Luis Álvarez de; Justicia, José; Cuerva, Juan M. (2014). "Recent applications of Cp2TiCl in natural product synthesis". Organic Chemistry Frontiers. 1 (1): 15–33. doi:10.1039/c3qo00024a.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.